Bottom line
No GLP-1 is FDA-approved specifically for polycystic ovary syndrome (PCOS). But because PCOS is fundamentally a condition of insulin resistance and weight dysregulation, GLP-1 drugs — especially semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) — have become a common off-label and adjunctive treatment. The 2023–2025 evidence base is substantial enough that most reproductive endocrinologists now consider GLP-1s a reasonable option after metformin for PCOS patients with overweight or obesity.
Expect 10–20% weight loss, better cycle regularity, reduced hyperandrogenism symptoms, and meaningful improvements in fasting glucose and HbA1c. Pregnancy is a contraindication — you'll need to stop the drug at least 2 months before trying to conceive.
What PCOS and GLP-1s have in common
PCOS is characterized by three core features (the Rotterdam criteria require 2 of 3):
- Ovulatory dysfunction (irregular or absent periods)
- Hyperandrogenism (elevated testosterone, DHEA-S; clinical signs
include hirsutism, acne, male-pattern hair loss)
- Polycystic ovarian morphology on ultrasound
The underlying driver in the large majority of PCOS patients is insulin resistance. Elevated insulin stimulates ovarian androgen production and disrupts the LH/FSH signaling that governs ovulation. This is why metformin — an insulin-sensitizer — has been a PCOS mainstay for decades.
GLP-1s improve insulin sensitivity through a different mechanism (slower gastric emptying, enhanced glucose-dependent insulin secretion, central appetite regulation leading to weight loss). That makes them complementary to metformin and — in patients with significant weight involvement — often more effective.
The evidence: what trials have shown
Semaglutide in PCOS. Several randomized trials between 2021 and 2025 showed semaglutide 1.0–2.4 mg weekly produces roughly 10–15% weight loss in PCOS patients over 6–12 months, with parallel improvements in menstrual cycle frequency (restoration of ovulation in 60–75% of treated patients in the larger studies), testosterone, SHBG, and HOMA-IR.
Liraglutide. Smaller but older studies (LEAD-Metabolism PCOS sub-group, 2017–2020) showed 5–8% weight loss and significant improvement in menstrual regularity.
Tirzepatide. No PCOS-dedicated RCT has published as of April 2026, but the 2024 real-world evidence from obesity medicine clinics shows weight loss and metabolic improvement comparable to its SURMOUNT data — about 20% mean loss at 15 mg. Reproductive endocrinologists increasingly prescribe it off-label for PCOS patients with significant obesity.
Metformin comparison. Head-to-head studies favor GLP-1s on weight loss (5–10 percentage points more) and show comparable or better effects on insulin resistance. Metformin remains preferred when cost is the binding factor or when pregnancy is planned within 3–6 months.
Which GLP-1 for PCOS?
There's no single right answer, but here's how prescribers typically triage:
Zepbound — first choice when significant weight loss is a goal (BMI ≥32), insurance cooperates, and pregnancy is not near-term. Highest efficacy; strong effects on free testosterone.
Wegovy — second choice when Zepbound isn't covered or when a longer real-world safety record is preferred. Better cardiovascular evidence matters less in young PCOS patients than in older obesity populations.
Ozempic — used when a type 2 diabetes or prediabetes diagnosis is present, making on-label coverage possible.
Saxenda (daily liraglutide) — the go-to for patients planning pregnancy in the next 12 months because its shorter half-life means a faster washout. Also the only GLP-1 approved for adolescents 12–17 with obesity, which matters for teen PCOS.
Wegovy Pill — a reasonable option for needle-averse patients with consistent morning routines.
Side effects that matter specifically in PCOS
GLP-1s' standard side effect profile applies. Two PCOS-specific considerations:
1. Enhanced fertility during weight loss. Restoration of ovulation can happen within weeks of starting treatment, often before the patient realizes it. Use reliable contraception from day one if pregnancy is not desired.
2. Oral contraceptive absorption. Slowed gastric emptying may theoretically reduce absorption of oral contraceptives, though the clinical data on this is weak. Many reproductive endocrinologists recommend a barrier backup for the first 4 weeks after each dose escalation.
Pregnancy and GLP-1s
GLP-1s are contraindicated in pregnancy. Animal studies show adverse fetal effects; human data is limited but not reassuring.
Standard guidance: stop the drug at least 2 months before planned conception (semaglutide's ~1 week half-life means it takes 5–6 weeks to clear; a 2-month buffer accounts for this plus individual variability). Liraglutide's shorter half-life allows a shorter washout.
If pregnancy is discovered while on drug, stop immediately and discuss with your OB. Register with the manufacturer's pregnancy registry (Novo Nordisk's for semaglutide/liraglutide; Lilly's for tirzepatide) — this is how post-marketing safety data for PCOS and other conditions accumulates.
Cost and access for PCOS patients
Because PCOS is not an FDA-approved indication for any GLP-1, insurance coverage depends on what else is documented:
- PCOS + BMI ≥30 or ≥27 with comorbidity → Wegovy or Zepbound
prior auth for weight management often approved.
- PCOS + type 2 diabetes or prediabetes → Ozempic on-label; widely
covered.
- PCOS alone without obesity or diabetes → coverage difficult;
cash programs often required.
Telehealth programs experienced with PCOS prescribing: [program:mochi-health] and [program:form-health]. Neither advertises a PCOS focus specifically, but both have high approval rates for the relevant PAs.
Monitoring while on GLP-1s for PCOS
At minimum, track every 3–6 months:
- Weight and waist circumference
- Menstrual cycle pattern
- Fasting glucose or HbA1c (especially if prediabetic)
- Total testosterone and SHBG (to track hyperandrogenism improvement)
Annual labs should include lipid panel, liver function, and TSH. If symptoms improve substantially, ask your prescriber whether dose reduction is appropriate — PCOS often requires lower maintenance doses than pure obesity treatment.
Next steps
Take the [tool:matcher] to find programs that handle PCOS prescribing routinely, or explore the full GLP-1 medication lineup and compare options.